posted
bellwetherreport.com: The Bellwether Report continues to track the recent developments surrounding CalbaTech, Inc via COMTEX
May 23, 2006
May 23, 2006 (M2 PRESSWIRE via COMTEX News Network) --
CalbaTech, Inc (OTCBB:CLBE), is a company that our research team will be tracking over the ensuing weeks. They recently came out with a significant corporate development, causing a market stir. The BWR Research Team will continue to bring its subscribers cutting edge research tools, and second to none customer service.
CalbaTech, Inc, an emerging life sciences company who is concentrating on providing products and platforms to the biotech and pharmaceutical research market and to academic institutions, this morning announced sales of $412,567 in the quarter, up thirty-one percent compared to sales of $314,820 in the first quarter of 2005.
James DeOlden, CalbaTech CEO, said the Company "anticipates that revenues will continue to increase significantly from operations in the coming year because two subsidiaries, Molecula, Inc. and KD Medical, Inc., have combined their operations to be more efficient and these subsidiaries are moving into a new facility that will increase and improve manufacturing capabilities, and will create new custom product offerings to the National Institutes of Health, as well as major universities and pharmaceutical companies.
"The new facility also affords KD Medical contract research opportunities for pharmaceutical companies in the region and KD expects to experience growth and greater profitability due to contracting with a larger company to OEM some of its products, producing anticipated savings to KD. This contract should make KD more competitive and result in an increase in revenues and profitability," CalbaTech's CEO said.
Mr. DeOlden also said that CalbaTech's wholly owned subsidiary, LifeStem, is on schedule to begin generating revenues from its Stem Cell Microbank(TM) service in the second quarter of 2006. LifeStem is the only company that will collect and store adult stem cells from two different cell sources for autologous banking.
"The Stem Cell Microbank(TM) process, for which LifeStem has filed a U.S. patent application, is based on the perspective that it is not necessary to harvest an amount of stem cells that is immediately capable of regenerating the entire immune system at the time of collection,"
CalbaTech's CEO said. "Rather the cells are collected in micro quantities and cryo-preserved for future cellular expansion prior to reintroduction into the owner. We also believe it is in the client's best interest to store stem cells from two tissue samples." Finally, the Company also announced net income of $1.18 million, or $0.01 a share, for the first quarter ended March 31, 2006, compared to a loss in the same period in 2005. The first quarter included a $1.8 million adjustment of derivative and warrant liability to fair value of the underlying securities.
Although there have been no corporate developments over the last couple of weeks, I feel this company is still a great trading opportunity. Shares are currently trading down over 4.0% on strong volume as shareholders grow impatient and unload their shares. At its current share price of $0.040, I feel you can't go wrong. The BWR Research Team will continue to follow the market sentiment on this company and numerous others.
To review research on small cap companies like CalbaTech, Inc, as well as many more exciting articles we encourage you to visit www.bellwetherreport.com. You can find these reports under the "Today's Articles" section. No credit Card Needed!!
The Bellwether Report will continue to research all of the markets to bring you exciting opportunities!! If you are interested in receiving more information on these small or large cap opportunities as well as other features of our site, feel free to sign up for a complimentary subscription to the #1 online investment tool www.bellwetherreport.com.
Companies looking to advertise with Bellwether Report should email jlee*bellwetherreport.com with the subject line (Advertising).
All material herein was prepared by the Bellwetherreport.com, (Bellwether) based upon information believed to be reliable. The information contained herein is not guaranteed by Bellwether to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Bellwether is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein. Bellwether may receive compensation in cash or shares from independent third parties or from the companies mentioned.
Bellwether's affiliates, officers, directors and employees may also have bought or may buy the shares discussed in this opinion and may profit in the event those shares rise in value.
Bellwether will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission.
You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and Bellwether undertakes no obligation to update such statements.
M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info*m2.com.
posted
Lower it went (.034) but with ridiculous volume... Some great news would make the SP grow up by +50% to +100%. Some bad news would however make it loose no more than 10% I think, cause it's already in the price. Some good news, simply, would provide smthg like +20% or +30% imo.
-------------------- ------------ I M O --------------- - BuyAtBottoms + SellAtHighs - ---------------------------------- Posts: 87 | From: Houston | Registered: Apr 2006
| IP: Logged |
posted
CLBE: 0.037 Target: 3X to 6X in 3 months. MMs have been accumulating CLBE for 3 months; PR expected soon. Will be profitable in 2006. A rare gem.
Watch list: RSHN: 0.0031 -- MMs will move her soon to unload their huge inventory; make sure you get your fair share when they do it.
Posts: 3228 | From: Michigan | Registered: Aug 2005
| IP: Logged |
posted
CalbaTech Contributes to Key Effort Supporting Stem Cell Research to Cure Diabetes, Other Major Diseases via COMTEX
May 30, 2006
IRVINE, Calif., May 30, 2006 /PRNewswire-FirstCall via COMTEX News Network/ --
CalbaTech, Inc. (OTC Bulletin Board: CLBE), an emerging life sciences company (http://www.CalbaTech.com) concentrating on banking adult stem cells for possible future therapeutic uses and providing products and platforms to the biotech, pharmaceutical research market and to academic institutions, today announced its stem cell subsidiary LifeStem, Inc. contributed five Stem Cell Microbank(TM) services to the Los Angeles chapter of the Juvenile Diabetes Research Foundation for its third annual gala "Finding A Cure: A Love Story Benefiting Stem Cell Research" held May 24th at the Beverly Hilton Hotel in Los Angeles.
This annual event benefits stem cell research with the potential to cure diabetes, plus other life threatening diseases including Alzheimer's, Parkinson's disease and Multiple Sclerosis. Country music star Garth Brooks was honored with the Angel Award along with Steve and Ann Radar who received the Caregiver Award. Country music singing star Trisha Yearwood was also in attendance. Previous award recipients at "Finding A Cure" include Nancy Reagan, James Taylor, Robin Williams, Michael J. Fox and Dana Reeve.
"We are delighted to have been part of this event and to contribute to its success. Our subsidiary, LifeStem, which is overseeing the MicroBank(TM) Service, is the only company to collect and store adult stem cells from two different cell sources for possible future therapeutic uses," said CalbaTech CEO James DeOlden. "Someday we will look back on events like this and realize the importance of this early work on stem cell research in conquering some of mankind's most difficult diseases. With the research efforts by organizations such as JDRF to find cures through the use of stem cells, our Stem Cell Microbank(TM) Service may provide the vehicle for people who bank their stem to take advantage of such cures. We obviously believe that our Stem Cell Microbank(TM) Service complements the research efforts of JDRF, and others, and we applaud their tireless efforts."
About CalbaTech
CalbaTech, Inc. (OTC Bulletin Board: CLBE) is an emerging life sciences company (http://www.CalbaTech.com) concentrating on providing products and platforms to the research market for biotech and pharmaceutical companies and to academic institutions.
About LifeStem
LifeStem, a wholly owned subsidiary of CalbaTech, is focused on services and technologies to facilitate the collection of adult stem cells, development of stem cell delivery devices for clinical applications and clinical applications of specific stem cell based therapies. LifeStem, in addition to being the first company to offer micro collection of stem cells, is also the first company to offer a collection service that collects and stores two different types of stem cells. The Company has filed patent applications for an endoscopic stem cell delivery device and its novel Stem Cell MicroBank(TM) service.
Contact: Paul Knopick E&E Communications (949) 707-5365 pknopick*eandecommunications.com
Note: Certain statements in this news release may contain "forward-looking" information within the meaning of rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Act of 1934 and are subject to the safe harbor created by those rules. We use words such as "anticipate," "believe," "expect," "future," "intend," "plan," and similar expressions to identify forward-looking statements. These statements including those related to being in a large and growing market, exhibiting rapid growth characteristics, and having a growth strategy, are forward looking statements. These forward looking statements are only predictions and are subject to certain risks, uncertainties and assumptions. Some of the risks, uncertainties and assumptions that could cause actual results to differ materially from estimates or assumptions in this press release include the risk that we will not be able to grow our revenues and market share, the risk that our prices do not remain competitive and the risk that we will not achieve profitability. Additional risks are identified and described in the Company's public filings with the Securities and Exchange Commission, including our most recent Report on Form 10-KSB, and Reports on Form 10-QSB and Form 8-K. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company's past performance is not necessarily indicative of its future performance. The Company does not undertake, and the Company specifically disclaims, any obligation to update any forward-looking statements to reflect occurrences, developments, events, or circumstances after the date of such statement.
SOURCE CalbaTech, Inc.
Paul Knopick of E&E Communications, +1-949-707-5365, pknopick*eandecommunications.com, for CalbaTech, Inc. http://www.prnewswire.com
Copyright (C) 2006 PR Newswire. All rights reserved.
Posts: 420 | From: Canada | Registered: Feb 2006
| IP: Logged |
posted
maybe this will get the attention it truly deserves now.Rode this one to the double digits a few times since last Fall and it surely runs fast and easy even on low volume.
posted
CalbaTech Posts Letter to Shareholders on Achievements, Future Business Strategies via COMTEX
June 13, 2006
IRVINE, Calif., June 13, 2006 /PRNewswire-FirstCall via COMTEX News Network/ --
CalbaTech, Inc. (OTC Bulletin Board: CLBE), an emerging life sciences company (http://www.CalbaTech.com ) concentrating on banking adult stem cells for possible future therapeutic uses and providing products and platforms to the biotech, pharmaceutical research market and to academic institutions, today in a letter to all shareholders said that a comparison of sixteen companies in the stem cell arena showed CalbaTech third in EBITDA (Earnings Before Income Taxes, Depreciation and Amortization) and first in average daily trading volume.
However, the study shows CalbaTech had the second lowest market capitalization. "We believe this means that CalbaTech has tremendous stock upside potential. If our revenues and profits begin to reach pro-forma projections, particularly with LifeStem's Stem Cell MicroBank(TM) Service to open this month, the stock price should respond accordingly," wrote James DeOlden, CEO. The entire letter follows:
Dear Fellow Shareholder:
We at CalbaTech, Inc. thank you for your investment in our Company. The goals at CalbaTech are two-fold: To acquire revenue generating Life Science "tools" companies, that provide products and platforms to researchers, forming a profitable base by which to provide the Company with cash flow and allow it to seek higher reward projects; and to develop those higher reward projects that will provide the opportunity for a greater upside to our shareholders. We believe we are well on our way to accomplishing both of these goals.
Research Reagents Division
In 2003, we acquired Molecula, LLC, a company in Sterling, Virginia, that sold transfection products. In 2004, we acquired KD Medical, a company in Columbia, Maryland, that supplied research products to more than 300 National Institute of Health (NIH) laboratories, as well as most of the major pharmaceutical companies. While both were generating revenue when acquired, neither was profitable. In the past year, we have worked diligently to make the Research Reagents Division the profitable base we intended.
The first step was to incorporate a new Molecula, Inc. in Nevada, and then combine the operations of Molecula and KD Medical into one facility to more efficiently capitalize on their synergistic operations. Next, marketing efforts were coordinated to take advantage of common markets. Finally, redundancies in the management teams of the two companies were eliminated. The result is that the Research Reagents Division reported a net profit for 2005 and again in the first quarter of 2006. Furthermore, this Division is reporting a 25% growth in revenue for the quarter ended March 31, 2006, as compared to the same period in 2005.
The next move is, literally, a move, into a new location. This Division will be moving into a new facility with two validated Class 100 clean rooms and a complete quality control laboratory that will be used to grow revenues in two different ways. One clean room will be used to increase the manufacturing capabilities of the KD Medical product offerings, so as to manufacture a higher quality of product, and to expand the current custom product offerings to the NIH as well as major universities and pharmaceutical companies. The second clean room will be utilized for other potential growth in revenue by allowing the Division to perform contract research for the many pharmaceutical companies located in this region.
Finally, the Research Reagents Division should also experience growth and greater profitability due to a recent understanding with a large media company to produce some of KD's routine media products. This is intended to allow KD to more aggressively sell these routine products, with greater profitability due to a decrease in redundant labor, and to enter markets that were previously unavailable due to cost competitiveness. This should result in an increase in revenues and allow KD to focus more attention to manufacturing custom products.
In summary, we believe that the Research Reagents Division has become a steady, growing, profitable foundation upon which we can build a greater return for our shareholders.
Cellular Therapies Division - LifeStem
In 2004, we purchased I-Stem from Dr. Jason R. Van Tassell, M.D. I-Stem owned the intellectual property to the Stem Cell Delivery Device, an endoscopic device capable of delivering adult stem cells directly to infarcted cardiac tissue. Dr. Van Tassel created the concept after hearing about an Illinois teenager who became a cardiac cripple after being shot in the heart by a nail gun. The teenager had adult stem cells injected into his blood stream resulting in cardiac tissue regeneration. While the teenager does not have completely normal cardiac function, the results were significant, allowing him functionality. Dr. Van Tassel reasoned that if stem cells injected into peripheral blood could cause significant cardiac tissue regeneration, then cells injected directly into the cardiac tissue would have even greater efficacy.
Subsequently the Company formed LifeStem, Inc., a wholly-owned subsidiary, to further I-Stem as well as to enter the new emerging field of banking adult stem cells for autologous use. This was determined after canvassing current stem cell banking services and realizing that there was a tremendous void to be filled, as the market had competitors at opposite poles. There are several companies collecting umbilical cord blood from newborns, which contain fertile stem cells, and there are other companies that are collecting autologous stem cells from adults in extremely inconvenient, invasive, costly, and time consuming ways. The former only helps those of the generation being born today whose parents have the foresight to take advantage of storing cord blood, and the latter does not provide non-invasive and convenient collection and storage of adult stem cells at a reasonable price.
We also determined that there were not any companies offering to collect adult stem cells from more than one tissue source. Some stem cells are more likely to develop into blood cells and similarly related tissues, while others are more likely to develop into bone, cartilage or muscle tissue. We therefore developed the process of harvesting stem cells in micro quantities to be cryopreserved for future transplantation into the client. We filed a patent application for our Stem Cell MicroBank(TM) Service, which is promulgated on the belief that it is unnecessary to collect an amount of stem cells sufficient to fully reconstitute one's entire immune system at the time of collection. LifeStem's Adult Stem Cell MicroBank(TM) is the only company to offer "micro" collections of stem cells from two different tissue sources thereby offering greater potential for treatments for multiple diseased conditions.
To a large degree, we believe that the adult stem cell collection and storage market mirrors the cosmetic surgery market, with its emphasis on proactive and preventative healthcare. People likely to have cosmetic surgery are concerned about quality of and longevity of life, they are health conscious, college-educated, and tend to seek non-traditional medical services. To this end, in December 2005, we signed a distribution agreement with Solana MedSpas, a developer and syndicator of medical spas, with 25 medspas currently open and operating and plans for more than 50 additional locations to open during 2006. In accordance with this agreement, adult stem cell collections will be performed at medspa locations using our Stem Cell Microbank(TM) Service. We are also working to contract with physician's offices to carry our Stem Cell MicroBank(TM) Service and believe that cosmetic surgeons, cardiologists, and orthopedists will be excellent distribution sites. With these agreements, we believe we will be ready to make an explosive entry into this marketplace as we perform the first collections in June.
First Quarter 2006 Financial Results/Stock Performance
The first quarter of this year is reflective of our belief in the CalbaTech model, as well as the actions we have taken over the past year. KD Medical, Molecula, and another of our other wholly-owned subsidiaries, Molecularware, Inc., all were profitable and as a whole experienced a 25% growth in revenue. LifeStem is primed for success as the pricing and cost structure of the Stem Cell Microbank(TM) Service will be profitable from each collection.
Recently, an industry source published information regarding each of the public companies competing in the stem cell arena. Of the sixteen companies listed, CalbaTech was listed third in EBITDA (Earnings Before Income Taxes, Depreciation and Amortization), and first in average daily trading volume, yet had the second lowest market capitalization. We believe this means that CalbaTech has tremendous stock upside potential. If our revenues and profits begin to reach our pro-forma projections, particularly with LifeStem's Stem Cell MicroBank(TM) Service set to open in June, the price of our stock should respond accordingly.
We have put the building blocks in place and have begun building a truly successful company. We are pleased that you have chosen to invest in CalbaTech. Thank you for the trust and continued support.
Sincerely, James DeOlden Chief Executive Officer
Note: Certain statements in this President's Letter may contain "forward looking" information within the meaning of rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Act of 1934 and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, may include forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will be accurate and actual results and future events could differ materially from those anticipated in such statements.
Contact: Paul Knopick E&E Communications (949) 707-5365 pknopick*eandecommunications.com
SOURCE CalbaTech, Inc.
Paul Knopick of E&E Communications, +1-949-707-5365, pknopick*eandecommunications.com, for CalbaTech, Inc. http://www.prnewswire.com
Copyright (C) 2006 PR Newswire. All rights reserved.
Posts: 420 | From: Canada | Registered: Feb 2006
| IP: Logged |
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
